Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Vaccines and Antiviral Agents

Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice

Julia C. Frei, Ariel S. Wirchnianski, Jennifer Govero, Olivia Vergnolle, Kimberly A. Dowd, Theodore C. Pierson, Margaret Kielian, Mark E. Girvin, Michael S. Diamond, Jonathan R. Lai
Terence S. Dermody, Editor
Julia C. Frei
aDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ariel S. Wirchnianski
aDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Govero
bDepartment of Medicine, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivia Vergnolle
aDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly A. Dowd
fViral Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theodore C. Pierson
fViral Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret Kielian
cDepartment of Cell Biology, Albert Einstein College of Medicine, Bronx, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Margaret Kielian
Mark E. Girvin
aDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael S. Diamond
bDepartment of Medicine, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA
dDepartment of Molecular Microbiology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA
eDepartment of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan R. Lai
aDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terence S. Dermody
University of Pittsburgh School of Medicine
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.01023-18
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIG 1
    • Open in new tab
    • Download powerpoint
    FIG 1

    Rs-DIIIs demonstrate favorable binding to DENV MAbs. (A) Domain organization of prefusion homodimeric E glycoprotein. One subunit is color coded by domain (EDI, red; EDII, yellow; and EDIII, blue); the other subunit is shown in gray. DENV-2 is shown as an example from Protein Data Bank (PDB) ID 1OAN (19). (B) Overlay of DENV-1 to -4 EDIIIs bound to the single-chain variable fragment (scFv) of 4E11 from PDB ID 3UZQ, 3UZV, 3UZE, and 3UYP (27). (C) The red spheres indicate library positions on DENV-2 EDIII that were allowed to vary in phage libraries (PDB ID 3UZV [27]). The inset shows the orientation of EDIII, with the A and G strands highlighted. (D) Sequence of rsDIII at the randomized positions. Red indicates substitutions with alanine or serine, and orange indicates other possible substitutions. (E) Reactivity profiles of phage expressing WT DENV-2 EDIII and rsDIIIs toward a panel of DENV MAbs: 2H12 and WNV-E111 (AB loop), 3H5 (FG loop), and M2 (FLAG). Wells coated with BSA served as a negative control. The data are from two experiments performed in duplicate and are plotted as means and standard deviations (SD).

  • FIG 2
    • Open in new tab
    • Download powerpoint
    FIG 2

    Biochemical characterization of rsDIIIs indicating abolishment of unfavorable epitopes. (A) Size exclusion chromatogram of WT and rsDIIIs indicating two populations of EDIII, aggregated and monomeric. The monomeric fraction was used in further experiments. AU, arbitrary units. (B) RsDIIIs bind only to MAb 4E11 with high affinity and show little or no binding to MAbs 2H12 and 3H5 by ELISA. In contrast, WT DENV-2 EDIII binds to all three antibodies. The data are graphed as means ± SD from the results of two experiments performed in triplicate. Abs., absorbance. (C) RsDIIIs bind only to MAb 4E11 and demonstrate no binding to MAbs 2H12 and 3H5 by BLI. RsDIIIs were captured on Ni-NTA sensors, followed by antibody association and dissociation. Antibody concentrations ranged from 27 to 0.01 nM for 4E11 and 2H12 and from 6 to 0.01 μM for 3H5. The data were fit to a global 1:1 binding model.

  • FIG 3
    • Open in new tab
    • Download powerpoint
    FIG 3

    The core structure of rsDIIIs relative to WT DENV-2 EDIII is maintained. (A) 1H-15N HSQC cross peaks for WT DENV-2 EDIII (black), rsDIII-Ala11 (red), and rsDIII-Ala30 (blue) overlap substantially. Residue labels for WT DENV-2 EDIII peaks that had nearby peaks in the rsDIII-Ala11 or rsDIII-Ala30 spectra are shown. Many cross peaks overlap between the spectra, indicating that the overall fold is similar between WT and rsDIII proteins. (B) RsDIII-Ala11 (red) and rsDIII-Ala30 (blue) residues that overlap assigned WT DENV-2 EDIII resonances were mapped onto the DENV-2 EDIII crystal structure (PDB ID 3UZV [27]). The green spheres represent points of mutation in rsDIIIs relative to the WT.

  • FIG 4
    • Open in new tab
    • Download powerpoint
    FIG 4

    RsDIIIs elicit broadly reactive serum responses across DENV serotypes 1 to 4. (A) Immunization and bleed schedule. (B) (Top) Serum endpoint titers against each immunogen reached a maximum by day 28 and remained constant through day 90. (Bottom) Serum antibody responses were not directed toward a hexahistidine tag-bearing control protein. Groups of 10 BALB/c mice were immunized, and serum reactivity was determined for each mouse and plotted as the mean ± SD. (C) ELISA against EDIIIs, with five representative serum samples from each immunogen group. The data are from a single experiment completed in duplicate.

  • FIG 5
    • Open in new tab
    • Download powerpoint
    FIG 5

    Engineered EDIIIs elicit potent cross-neutralizing antibodies. (A) Aggregate serum neutralization data for 10 mice against DENV-1 to -4. The lowest serum dilution tested for each sample was 1:20, followed by serial 2-fold dilutions. Naive mice served as the negative control. For DENV-1 to -3, sera from WT DENV-2 EDIII- and rsDIII-Ala30-immunized mice showed similar levels of neutralization, with the IC50s indicated as serum titers. Sera from rsDIII-Ala11-immunized mice demonstrated weak neutralization. Naive sera resulted in partial neutralization at the lowest dilution tested. The data are from two experiments performed in duplicate and are plotted as means ± SD. (B) Neutralization curves for individual mice against DENV-1 to -3 were plotted, and both 50% and 80% focus reduction neutralization titers were determined and plotted. The mean FRNT50 and FRNT80 values for WT DENV-2 EDIII-immunized and rsDIII-Ala30-immunized mice were not significantly different (ns), whereas the mean FRNT50 and FRNT80 values for WT DENV-2 EDIII- and rsDIII-Ala11-immunized mice were significantly different by Kruskal-Wallis one-way ANOVA with Dunn's multiple-comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001). For serum samples that did not reach 50% or 80% neutralization at the highest concentration of serum tested (1:20 dilution), a serum dilution of 1:5 was arbitrarily assigned.

  • FIG 6
    • Open in new tab
    • Download powerpoint
    FIG 6

    AG129 passive-transfer model of DENV-2 D2S20 infection, and ADE assay. (A) Pooled sera from days 60 and 90 from WT DENV-2 EDIII- and rsDIII-Ala30-immunized mice were transferred to groups of 5 AG129 mice prior to infection with the mouse-adapted strain D2S20 of DENV-2. Pooled naive sera served as the negative control. The mice were monitored until death. All the mice from the WT- and rsDIII-Ala30-immunized groups died on day 5, while naive mice had a mean survival of 7 days. By log rank test, there was a statistically significant trend (P = 0.006) toward shortened survival in the EDIII immunogen-treated groups relative to mice receiving naive serum, suggesting that the immunogen-elicited serum antibodies were insufficient for protection and instead resulted in ADE. The data are from a single experiment. (B) DENV-2 16681 RVPs were incubated with serial dilutions of the indicated mouse sera for 1 h at 37°C, followed by infection of K562 cells. Infection was measured by flow cytometry 48 h later. The fold enhancement was calculated in reference to the minimal infection of K562 cells in the absence of antibody. Shown is one representative experiment of two; the error bars indicate the ranges of duplicate technical replicates.

Tables

  • Figures
  • Additional Files
  • TABLE 1

    Apparent dissociation constants for rsDIIIs

    AntibodyParameterValue
    WT DENV-2 EDIIIrsDIII-Ala11rsDIII-Ala30
    4E11kd/ka (nM)0.01 ± 0.0020.45 ± 0.110.03 ± 0.001
    ka (M−1 s−1)(1.4 ± 0.008) × 106(27 ± 1.2) × 104(220 ± 1.6) × 104
    kd (s−1)(19 ± 2.2) × 10−6(120 ± 3.9) × 10−6(54 ± 2.6) × 10−6
    2H12kd/ka (nM)1.1 ± 19
    ka (M−1 s−1)(1.8 ± 3.3) × 106
    kd (s−1)(92 ± 2.1) × 10−5
    3H5kd/ka (nM)120 ± 0.32
    ka (M−1 s−1)(1.4 ± 1.4) × 103
    kd (s−1)(1.6 ± 0.04) × 10−4

Additional Files

  • Figures
  • Tables
  • Supplemental material

    • Supplemental file 1 -

      Table S1 (List of chemical shifts for WT DENV-2 EDIII.)

      XLSX, 65K

PreviousNext
Back to top
Download PDF
Citation Tools
Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice
Julia C. Frei, Ariel S. Wirchnianski, Jennifer Govero, Olivia Vergnolle, Kimberly A. Dowd, Theodore C. Pierson, Margaret Kielian, Mark E. Girvin, Michael S. Diamond, Jonathan R. Lai
Journal of Virology Aug 2018, 92 (18) e01023-18; DOI: 10.1128/JVI.01023-18

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice
Julia C. Frei, Ariel S. Wirchnianski, Jennifer Govero, Olivia Vergnolle, Kimberly A. Dowd, Theodore C. Pierson, Margaret Kielian, Mark E. Girvin, Michael S. Diamond, Jonathan R. Lai
Journal of Virology Aug 2018, 92 (18) e01023-18; DOI: 10.1128/JVI.01023-18
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

dengue virus
domain IIII
immunogen
phage display
protein engineering
vaccine

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514